Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: A case-report and review of the literature

Journal of Gastrointestinal and Liver Diseases

Volumn 20, Issue 1, 2011, Pages 77-80

  Eriksson, Carl ^a   Gustavsson, Anders ^a,c   Kronvall, Thomas ^b   Tysk, Curt ^a,c  

^a Department of Medicine   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c ÖREBRO UNIVERSITY   (Sweden)

Author keywords

Adverse effects; Bosentan; Hepatotoxicity; Portopulmonary hypertension

Indexed keywords

AMBRISENTAN; BOSENTAN; FUROSEMIDE; PREDNISOLONE; SILDENAFIL; SPIRONOLACTONE;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ASCITES; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; CASE REPORT; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; PORTOPULMONARY HYPERTENSION; PRURITUS; RASH; REVIEW; SIDE EFFECT;

ADULT; ANTIHYPERTENSIVE AGENTS; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; SULFONAMIDES;

EID: 79953654350     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Porres-Aguilar M, Zuckerman MJ, Figueroa-Casas JB, Krowka MJ. Portopulmonary hypertension: state of the art. Ann Hepatol 2008; 7:321-330.
2. Stauber RE, Olschewski H. Portopulmonary hypertension: short review. Eur J Gastroenterol Hepatol 2010; 22:385-390.
3. Humbert M. Update in pulmonary hypertension 2008. Am J Respir Crit Care Med 2009; 179:650-656.
4. Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 2003; 52:1355-1362.
5. Kawut SM, Krowka MJ, Trotter JF, et al. Clinical risk factors for portopulmonary hypertension. Hepatology 2008; 48:196-203.
6. Kenyon KW, Nappi JM. Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother 2003;37:1055-1062.
7. Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2009:CD004434.
8. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007;30:338-344.
9. Beghetti M. Bosentan in pediatric patients with pulmonary arterial hypertension. Curr Vasc Pharmacol 2009;7:225-233.
10. Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005;25:502-508.
11. Bjornsson E. Drug-induced liver injury: Hy's rule revisited. Clin Pharmacol Ther 2006; 79:521-528.
12. Dwyer N, Jones G, Kilpatrick D. Severe hepatotoxicity in a patient on bosentan upon addition of methotrexate: reversible with resumption of methotrexate without bosentan. J Clin Rheumatol 2009; 15:88-89.
13. Nagai Y, Okada E, Mihara S, Sato K, Ohi S, Ishikawa O. Severe liver dysfunction due to bosentan in a patient with mixed connective tissue disease. Eur J Dermatol 2008; 18:190-191.
14. Mulchey K, Bshouty Z. An atypical presentation of liver enzyme elevation resulting from bosentan use. Can Respir J 2009;16:e54-e56.
15. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002;121:1860-1868.
16. Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant 2007; 26:63-69.
17. Lavelle A, Sugrue R, Lawler G, et al. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. Eur Respir J 2009; 34:770-771.
18. Hoeper MM, Olsson KM, Schneider A, Golpon H. Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy. Eur Respir J 2009; 33:1518-1519.
19. Hoeper MM. Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy? Eur Respir J 2009; 34:529-530.
20. McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009;135:122-129.
21. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008;31:407-415.
22. Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001;69:223-231.